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Abstract—The preparation of various 5-[alkoxy-(4-nitro-phenyl)-methyl]-uracils with alkyl chain lengths C1–C12 is described. The
synthesis is based on the preparation of 5-[chloro-(4-nitro-phenyl)-methyl]-uracil and subsequent substitution of chlorine with
appropriate alcohols. The resulting ethers were tested for their cytotoxic activity in vitro against five cancer cell lines. The com-
pounds were less active in lung resistance protein expressing cell lines, suggesting the involvement of this multidrug resistant protein
in control of the biological activity. Cytotoxic substances induced rapid inhibition of DNA and modulation of RNA synthesis
followed by induction of apoptosis. The data indicate that the biological activity of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uracils
depends on the alkyl chain length.
 2007 Elsevier Ltd. All rights reserved.
Compounds derived from 5-alkyluracil are well known
for their biological activity. Some of them, for exam-
ple, have been described as suitable agents for treating
various diseases caused by excessive cell proliferation,
such as in the treatment of various cancers1 or treat-
ment of proliferative diseases mediated by second mes-
sengers.2 The most potent 5-alkyluracils inhibited the
proliferation of leukemia, lymphoma, and solid tu-
mor-derived cell lines at micromolar concentrations.3
Our research is focused on derivatives of 5-alkoxyura-
cils with anticancer activity. In this paper we describe
the synthesis and cytotoxic activity of 5-[alkoxy-(4-ni-
tro-phenyl)-methyl]-uracils having various alkyl chain
lengths.
The reaction of uracil with benzaldehyde is reported to
afford the appropriate derivative 2.4 If 4-nitrobenzalde-
hyde is used instead, 5-[hydroxy-(4-nitro-phenyl)-
methyl]-uracil 6 results as is described in the same pub-
lication (Scheme 1).
In our hands the reaction does not lead to compound 6,
but rather to a mixture of 5-[chloro-(4-nitro-phenyl)-
methyl]-uracil 3 and 5,5 0-(4-nitrophenyl)-methyl-bis-
1H-pyrimidine-2,4-dione 4 instead. We successfully tried
to find reaction conditions for selective preparation of
each derivative (Scheme 2).
Derivative 4 has been prepared recently by nitration of
5,5 0-phenylmethylene-bis-uracil and patented in the
class of anti-ictogenic or anti-epileptogenic agents.5
0960-894X/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmcl.2007.09.022
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activity.
* Corresponding author. Tel./fax: +420 585634405; e-mail addresses:
hajduchm@gmail.com; hlavac@prfnw.upol.cz
 These authors contributed equally to the work.
Scheme 1. Reaction of uracil with benzaldehyde and p-nitrobenzalde-
hyde according to Ref. 4.
Available online at www.sciencedirect.com
Bioorganic & Medicinal Chemistry Letters 17 (2007) 6647–6650
Author's personal copy
The chlorine atom of derivative 3 is very reactive. When
treated with sodium azide the appropriate azide 5
results, with DMF/water the alcohol 6 is obtained and
with alcohols the desired ethers 7 are formed (Scheme 3).
The prepared compounds 4–7 were tested for their cyto-
toxic activity against five tumor cell lines under in vitro
conditions. Compounds 4, 5 were found to be quite
inactive with IC50 above 100 lM. However, the activity
of first prepared ethers differed. For this reason, we
decided to prepare a series of alkoxyderivatives 7 with
various alkyl chain lengths. Compounds with longer al-
kyl chains (heptyl 7g to dodecyl 7l) exhibited relatively
higher cytotoxic activity in CEM and K562-Tax leuke-
mia cells. In these lines, the only exception in the activity
trend is derivative 7f (Fig. 1).
In cell lines A549, CEM-DNR-B, and K-562, the cyto-
toxic activity also increases with increasing chain length
(7-9 carbons) and then decreases. Again, derivative 7f
exhibits exceptions in the activity trend (Fig. 2).
Branching of alkyls reduces the activity, because
compounds 7m, n, and o are quite inactive.
For better understanding of the biological uniqueness of
compound 7f we have studied its activity in more detailed
analysis of the cell cycle, apoptosis, DNA and RNA syn-
thesis using CEM T-lymphoblastic leukemia cells.6,7 The
potency of compound 7f was compared to those of the
two most potent substances 7g and 7h, whose alkyl chain
lengths differ only by one or two carbon lengths, respec-
tively. Analyses were performed at equiactive concentra-
tions corresponding to 1· IC50 and 5· IC50.
Interestingly, the cytotoxic activity of the alkoxyderiva-
tives 7f–h was accompanied by rapid inhibition of DNA
synthesis at concentration 5· IC50 (Fig. 3).
However, at concentration 1· IC50 inhibition of DNA
synthesis is significant only for derivative 7f. Moreover,
there was an apparent increase of RNA synthesis in
compounds 7g and 7h but inhibition in 7f at 1· IC50,
while in 5· IC50 the total RNA synthesis was inhibited
in cells treated with any of the compounds. Based on
these data we hypothesize that the transient increase of
Scheme 2. Reaction of uracil with p-nitrobenzaldehyde.
Scheme 3. Preparation of 5-[(alkoxy-(4-nitrophenyl)-methyl]-uracil 7
and other derivatives.
Figure 1. Cytotoxic activity of compounds 7a–7j and control agent
(carboplatin) as a function of chain length in LRP negative CEM and
K562-Tax leukemia cell lines.
Figure 2. Cytotoxic activity of compounds 7a–7j and control agent
(carboplatin) related to chain length in LRP positive A549, CEM-
DNRB, and K562 cell lines.
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RNA synthesis at 1· IC50 in cells treated with 7g and 7h
is due to compensatory mechanisms, for example, trea-
ted cells are compensating insufficiency of macromole-
cules via increased RNA biosynthesis.
All three compounds 7f–h induced apoptosis at 5· IC50
concentrations, but did not cause any significant cell cy-
cle alterations in treated CEM cells (Fig. 4). Interest-
ingly, at concentration 1· IC50 only 7f caused
significant apoptosis within 24 h. This finding rather
contrasts with the lower cytotoxic potency of compound
7f in 3-day cytotoxic MTT assay compared to structures
7g, 7h and suggests that chemical or metabolic stability
of 7f could explain the incoherent biological behavior of
the compound.
Cell lines A549, CEM-DNR-B, and K-562 were gener-
ally more resistant to this class of compounds. Indeed,
cell lines A549, CEM-DNR-B, and K-562, express con-
sistently significant concentrations of lung resistance
protein (LRP) but not other multidrug resistance associ-
ated proteins compared to CEM and K562-Tax cells.8
Thus, we hypothesize that the cytotoxic activity of 5-
[alkoxy-(4-nitro-phenyl)-methyl]-uracils is controlled
by the multidrug resistance associated protein LRP.
Interestingly, the cytotoxic activity of substances 7g
and 7h in contrast to derivative 7f is active in LRP neg-
ative, but p-glycoprotein (PgP) positive K562-Tax cells.
This means that they were not influenced by expression
of multidrug resistance associated protein PgP, suggest-
ing activity of compounds in PgP overexpressing
tumors.8 However, the cytotoxic potency of all com-
pounds was reduced in CEM-DNR-bulk cells, which
are, in addition to LRP positivity, characterized by
overexpression of the multidrug resistance protein 1
(MRP) and decreased expression of topoisomerase IIa
gene.8 These data suggest that compounds 7f–h are
transported via LRP and may, directly or indirectly, tar-
get topoisomerase IIa. The involvement of MRP1
dependent transportation is not clear, since derivatives
were relatively potent in another MRP1 positive cell line
A549.8
In conclusion, the synthesized derivatives of 5-[(azido-
(4-nitrophenyl)-methyl]-uracil (5), 5-[hydroxy-(4-nitro-
Figure 3. Summary of RNA/DNA analysis for CEM cancer cell line
treated with compounds 7f–h. Data are expressed as a percentage of
positive cells in the total cellular population. 6,7
Figure 4. Summary of conventional cell cycle and apoptosis analysis
for CEM cancer cell line treated with compounds 7f–h. Data are
expressed as a percentage of cells with corresponding DNA content in
the total cellular population. 6,7
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phenyl)-methyl]-1H-pyrimidine-2,4-dione (6), 5,5 0-(4-
nitrophenyl)-methyl-bis-1H-pyrimidine-2,4-dione (4) as
well as the 5-[(alkoxy-(4-nitrophenyl)-methyl]-uracil (7)
substituted with low alkyl chain did not exhibit any sig-
nificant cytotoxic activity against cancer lines. Activity
increases with chain lengths continuously in lines
CEM and K562-Tax. In ethers 7 with longer chains
(from nonyl to undecyl), the activity decreases in LRP
positive cell lines A549, K562, and CEM-DNR-B. Com-
pounds 7f–h, which were studied in the DNA/RNA syn-
thesis inhibition test, exhibited similar activity in
concentration 5· IC50, where the synthesis of both nu-
cleic acids was inhibited. Inhibition of de novo DNA
and RNA synthesis is the most probable reason for ra-
pid induction of apoptosis in treated cells.
At the concentration 1· IC50, only compound 7f effec-
tively inhibited both synthesis of DNA and RNA and
induced apoptosis. However, the structure was rela-
tively inactive in a 3-day cytotoxic assay. The excep-
tional behavior of the hexylderivative 7f may be
caused by chemical or metabolic stability or differen-
tial affinity to the multidrug resistance associated pro-
teins. Compounds 7g, 7h left the DNA synthesis
uninfluenced, but caused an increase in RNA synthe-
sis. This may be caused by promotion of compensa-
tory mechanisms. Therefore, the apoptosis at this
concentration was not apparent within the first 24 h
of treatment.
The bulky alcohols used to form ethers 7m–o did not en-
hance the activity to any noticeable extent.
The activity of individual enantiomers and nucleosides
derived from derivatives 7 is now under intensive exam-
ination and will be published separately.
Acknowledgment
This study was supported in part by the Ministry of
Education of the Czech Republic (MSM 6198959216
and LC07017).
Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/
j.bmcl.2007.09.022.
References and notes
1. Verdine, G. L.; Deng, L. WO 9839334, 1998; Chem. Abstr.
1998, 129, 239906.
2. Leigh, A.; Michnick, J. K. A.; Underiner, G.; Rice, G. C.;
Klein, J. P.; Reddy, D. WO 9422449, 1994; Chem. Abstr.
1994, 122, 151367.
3. Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Spalluto, G.;
Garuti, L.; Roberti, M.; Pani, A.; Perra, G.; Scintu, F.;
Pinna, N.; Musiu, C.; La Colla, P. Anti-cancer drug design
1996, 11, 597.
4. Lam, B. L.; Pridgen, L. N. J. Org. Chem. 1986, 51, 2592.
5. Weaver, Donald F.; Guillain, Buhendwa Musole. PCT Int.
Appl. Patent WO 2006070292 (2006), Chem. Abstr. 2006,
145, 124599.
6. Darzynkiewicz, Z.; Juan, G. Current Protocols in Cytom-
etry. In Robinson, J. P., Ed.; John Wiley & Sons, Inc., 1997,
Chapter 7; Unit 7.7.
7. Larsen, J. K.; Jensen, P. O.; Larsen, J. Current Protocols in
Cytometry. In Robinson, J. P., Ed.; John Wiley & Sons,
Inc., 1997, Chapter 7; Unit 7.12.
8. Noskova, V.; Dzubak, P.; Kuzmina, G.; Ludkova, A.;
Stehlik, D.; Trojanec, R.; Janostakova, A.; Korinkova, G.;
Mihal, V.; Hajduch, M. Neoplasma 2002, 49, 418.
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a b s t r a c t
A series of uridine analogues modified at the 5-position with the 5-[alkoxy-(4-nitrophenyl)-methyl]
moiety was synthesized. Nucleosides were formed as a mixture of two diastereoisomers, which were
separated and tested for their cytotoxic activity in vitro against different cancer cell lines and for anti-
microbial activity. Relationships between structure and the above mentioned activities were studied. The
cytotoxic activity was slightly increased in some cases by transformation of bases to nucleosides.
Depending on the length of the alkyl chain increased cytotoxic and antimicrobial activity were noted. The
cytotoxic activity of the nucleosides was not due to cell cycle alterations, DNA and/or RNA synthesis.
 2010 Elsevier Masson SAS. All rights reserved.
1. Introduction
Modern synthesis in the field of drug discovery is focused on
several types of derivatives. Nucleoside analogues, as potential
inhibitors of nucleic acid metabolism, play a significant role in
this area. In this context, we could mention as examples, the
reverse transcriptase inhibitors as potential AIDS therapies [1,2]
as well as inhibitors of thymidylate synthase used for the treat-
ment of leukemias or solid tumors [3,4]. Since the discovery of
the anticancer agent 5-fluorouracil, which has been used against
cancer for about 40 years, or drugs possessing antiviral activity,
such as 5-ethyl-20-deoxyuridine, investigation of the chemistry of
pyrimidine nucleosides modified at the 5 position has grown
extensively. The synthesis of alkoxy-uracil derivatives [5e13] and
their use as sensitive and valuable markers for studies on DNA
oxidation damage, has been described [14]. Also, another
5-modified uracil e 5,50-(4-nitrophenyl)-methyl-bis-1H-pyrimi-
dine 2,4-dione - has been shown to possess significant biological
properties and is patented in the class of anti-ictogenic or anti-
epileptogenic agents [15].
Our recent interest was centered on the 5 position of pyrimidine
nucleobases as potential anticancer agents. We modified the above
mentioned alkoxy-uracils by introducing a nitro-phenylmoiety and
reported the synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-
uracils 3ae3o (Scheme 1) and studied their in vitro anticancer
activity against five tumor cell lines under in-vitro conditions [16].
2. Results and discussion
2.1. Chemistry
Despite finding an interesting relationship between structure
and cytotoxic activity, the values of IC50 remained beyond micro-
molar concentrations. Consequently, we decided to convert these
structures into the ribonucleosides in order to improve solubility
and increase their possibility to interact with the enzymes
responsible for nucleic acids transformation and/or biosynthesis.
Now we have selected derivatives 3fe3i with the highest
activity and transformed them into the corresponding nucleosides.
The Vorbrüggenmethod [17]e as themost widely used reaction for
the preparation of ribonucleosides - was used. This reaction utilizes
silylated nucleobases and strong Lewis acids.
The synthesis was initiated by silylation of the starting
compounds 3fe3i (Scheme 2). Silylated uracils reacted with
* Corresponding author. Tel.: þ420 585 634 405; fax: þ420 585 634 467.
E-mail address: hlavac@orgchem.upol.cz (J. Hlavác).
1 Both authors contributed equally to the work.
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protected sugar in the presence of 1.1 equivalents of TMSOTf at
room temperature to afford benzoylated ribonucleosides 4fe4i that
were formed as a mixture of two diastereoisomers.
The separation of diastereoisomers was not simple due to the
similar properties of both isomers. The isomeric structures from
each mixture 4fe4i, however, had almost the same Rf and it was
therefore very difficult to separate them in amounts sufficient for
all studies and analyses. This separation was very sensitive to the
presence of water and size of column. Furthermore, a carefully
chosen gradient of the mobile phase was one of the most influen-
cial factors. Nevertheless, we have found an acceptable mobile
phase and conditions for separation by silica gel column chroma-
tography. Two diastereoisomers 5fe5i and 6fe6i from each
mixture 4fe4iwere isolated using methanol in chloroform (0e5%).
Treatment of ribonucleosides 5fe5i and 6fe6i with methanolic
ammonia at room temperature afforded the nucleosides 7fe7i and
8fe8i.
2.2. Cytotoxic activity
The prepared nucleosides 7fe7i and 8fe8i were tested under
in-vitro conditions for their cytotoxic activity against cancer cell
lines including drug sensitive (CEM and K-562) as well as drug
resistant (CEM-DNR-B and K-562 TAX) cell lines and A549 cells as
representative of solid tumors (Table 1) [18,19]. Cytotoxic activity
was analyzed in comparison to purine based anticancer agents
6-thioguanine and fludarabine. Although pyrimidine derivative
5-fluorouracil is structurally more related to our compounds, it was
not used as a comparative agent due to low activity in hemato-
poietic tumors, Figs. 1e5 show the activity-chain length depen-
dence. Compounds with longer alkyl chains exhibited a trend to
higher cytotoxicity in all tested cell lines. Nucleosides are not
always more potent than the free bases. The most active
compounds 7h, 7i and 8h, 8i were tested for their effect on the cell
cycle alterations including pH3Ser10 positivemitotic cells, apoptosis,
DNA and RNA synthesis inhibition (Table 2) in treated versus
control CEM T-lymphoblastic leukemia cells. Analyses were per-
formed at equiactive concentrations corresponding to 1 IC50 or
5 IC50 in a 24 h treatment interval. However, in these assays we
did not observe significant changes in cell distribution during the
cell cycle or differences in percentage of mitotic cells based on the
monitoring of pH3Ser10 positivity. All tested compounds provided
massive induction of apoptosis at 5 IC50 which was accompanied
by complete inhibition of DNA and RNA synthesis. However, at
a concentration of 1 IC50 we observed only small differences in
DNA/RNA synthetic activity suggesting that nucleic acid biosyn-
thesis is not a primary target of our compounds. On the contrary,
control agents, 6-thioguanine and fludarabine, inhibited DNA and/
or RNA synthesis even at low cytotoxic concentrations (Table 2).


























a) R = -CH3
b) R = -CH2CH3
c) R = -(CH2)2CH3
d) R = -(CH2)3CH3
e) R = -(CH2)4CH3
f) R = -(CH2)5CH3
g) R = -(CH2)6CH3
h) R = -(CH2)7CH3
i) R = -(CH2)8CH3
j) R = -(CH2)9CH3
k) R = -(CH2)10CH3
l) R = -(CH2)11CH3
m) R = -i-Pr
n) R = -s-But
o) R = -t-But
a) 4-nitrobenzaldehyde, conc. HCl, reflux, 4h
b) alcohol, reflux, 4h


























a) hexamethyldisilazane, (NH4)2SO4, 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose, trimethylsilyl trifluoro-methanesulfonate,
anhydrous 1,2-dichloroethane, RT, 2 days;
b) MeOH/NH3, RT, 6 days
3
4
f) R = -(CH2)5-CH3
g) R = -(CH2)6-CH3
h) R = -(CH2)7-CH3

















5f) R = -(CH2)5-CH3 ; [α]D25 +151.9
5g) R = -(CH2)6-CH3 ; [α]D25 +32.7
5h) R = -(CH2)7-CH3 ; [α]D25 +38.5
5i) R = -(CH2)8-CH3; [α]D25 +90.2
6f) R = -(CH2)5-CH3 ; [α]D25 +213.9
6g) R = -(CH2)6-CH3 ; [α]D25 +48.6
6h) R = -(CH2)7-CH3 ; [α]D25 +56.8
6i) R = -(CH2)8-CH3 ; [α]D25 +56.4
f) R = -(CH2)5-CH3
g) R = -(CH2)6-CH3
h) R = -(CH2)7-CH3
i) R = -(CH2)8-CH3
Scheme 2. Preparation of nucleosides 7fe7i and 8fe8i.
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2.3. Antimicrobial activity
The compounds were also tested for their antimicrobial activity
(see Table 3) against standard reference gram-positive and gram-
negative bacterial strains (Enterococcus faecalis CCM 4224, Staphy-
lococcus aureus CCM 3953, Escherichia coli CCM 3954 and Pseudo-
monas aeruginosa CCM 3955) from the Czech Collection of
Microorganisms (CCM, Faculty of Science, Masaryk University
Brno), and against gram-positive and gram-negative bacteria
obtained from clinical material of patients treated at University
Hospital in Olomouc (methicillin resistant S. aureus e MRSA,
Staphylococcus haemolyticus, E. coli and P. aeruginosa) with resis-
tance to fluoroquinolones used in clinical practice. Only the octyl
and nonyl derivatives 7h, 8h and 7i, 8i showed slight activity
against E. faecalis CCM 4224, S. aureus CCM 3953, S. aureus MRSA
and S. haemolyticus.
3. Conclusion
In conclusion, insertion of a ribose moiety into nucleosides
derived from 5-[alkoxy-(4-nitro-phenyl)-methyl]-uracil did not
bring about a significant increase of cytotoxic activity against
cancer lines in comparison to the analogous free bases. The activity
of these nucleosides was higher in drug sensitive than in drug
resistant cancer lines and was independent of the chirality of the
molecule. In contrast to the free bases, the nucleosides exhibited
only weak activity against several bacterial strains suggesting
specific target(s) in eukaryotic cells.
Because the activity increases with chain length in both anti-
cancer as well as antimicrobial activity, derivatives with longer




Melting points were determined on a Boetius stage and are
uncorrected. 1H NMR spectra were measured in DMSO-d6 at 300 K
on a Bruker Avance 300 spectrometer (300 MHz with TMS as an
internal standard; chemical shifts are reported in ppm, and
coupling constants in Hz). Mass spectrometric experiments were
performed using a triple quadrupole mass spectrometer TSQ
Quantum Access and chromatographic analysis were performed
using ultra-high pressure liquid chromatograph Accela (both from
Thermo Scientific, San Jose, CA, USA). HPLC experiments were
performed using Dionex liquid chromatograph (P 680 HPLC Pump,
PDA-100 Photodiode Array Detector). Preparative chromatography
was performed with using of Sepacore chromatography system
(Büchi). Optical rotations were recorded at the Sodium D line with
a polarimeter at room temperature.
4.1.1. 20,30,50-tri-O-benzoyl-b-D-ribofuranosyl-5-[hexyl-(4-nitro-
phenyl)-methyl]-pyrimidine-2,4-dione (4f), (5f), (6f)
5-[Hexyl-(4-nitro-phenyl)-methyl]-1H-pyrimidine-2,4-dione
(3f) (600 mg, 1.7273 mmol) was heated in hexamethyldisilazane
(15 ml) at 140 C with (NH4)2SO4 (approximately 5 mg) for 8 h.
After that it was evaporated and residue was dissolved in anhy-
drous 1,2-dichloroethane (20 ml). To this solution, 1-O-acetyl-
2,3,5-tri-O-benzoyl-b-D-ribofuranose (871.4 mg, 1.7273 mmol) and
trimethylsilyl trifluoro-methanesulfonate (345 ml, 1.9061 mmol)
were added. This mixture was stirred at room temperature for 2
days, washed with water (20 ml) and ethyl acetate (60 ml), dried
over sodium sulphate, filtered and evaporated to dryness. Yield of
Table 1
Cytotoxic activity of standard anticancer agents and derivatives 7fe7i and 8fe8i on human malignant cell lines of different tissue origin and drug resistance profile.
Compounds R A 549 CEM IC50 (mM)
CEM-DNR-B
K 562 K562-TAX
6-thioguanine 2.82  1.2 2.98  0.8 9.47  1.2 1.54  0.07 3.9  0.56
fludarabine 47.44  9.0 19.49  0.9 1.01  0.34 267  22.5 0.26  0.15
7f hexyl 121.3  23.4 39.8  1.9 131.0  7.1 58.4  3.1 141.4  14.3
7g heptyl 39.8  13.5 12.8  3.5 103.7  9.8 33.6  1.8 42.8  3.6
7h oktyl 38.7  11.0 11.4  1.7 34.6  2.4 15.1  2.8 33.1  3.4
7i nonyl 23.1  11.0 7.9  1.4 32.3  3.0 10.9  1.4 14.6  3.5
8f hexyl 156.0  22.0 45.5  16.5 145.8  12.6 64.5  12.3 136.9  14.3
8g heptyl 69.9  35.8 29.0  4.9 95.6  12.1 36.7  2.2 52.3  4.4
8h oktyl 39.7  10.3 16.9  5.1 36.6  3.1 24.7  7.7 34.4  2.7
8i nonyl 29.1  11.1 10.0  1.0 33.8  2.8 13.0  1.1 23.9  5.8
Fig. 1. Cytotoxic activity of compounds 3fe3i, 6fe6i and 7fe7i as a function of chain
length in the CEM cell line.
Fig. 2. Cytotoxic activity of compounds 3fe3i, 7fe7i and 8fe8i as a function of chain
length in the K562 cell line.
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crude product (4f) (mixture of diastereoisomers) 852.3 mg (62%).
Two diastereoisomers (5f) and (6f) were isolated in this order from
the mixture by silica gel column chromatography using methanol
in chloroform (0e5%).
4.1.1.1. Isomer (5f). Yield 189.3 mg (14%), m.p. 75e77 C,
[a]D25 þ 151.9 (c 0.027, CHCl3); 1H NMR (DMSO-d6): d 0.76e0.81 (m,
3H, CH3); 1.12e1.26 (m, 6H, CH2); 1.37e1.47 (m, 2H, CH2);
3.23e3.44 (m, 2H, CH2); 4.63e4.65 (m, 2H, H-50); 4.77e4.81 (m,1H,
H-40); 5.34 (s, 1H, CH); 5.94e6.02 (m, 2H, H-20, H-30); 6.25 (d, 1H, H-
10, J ¼ 4.2 Hz); 7.41e7.51 (m, 6H, Ph); 7.57 (d, 2H, Ph, J ¼ 8.7 Hz);
7.61e7.69 (m, 3H, Ph); 7.82 (s, 1H, Ph); 7.86 (d, 2H, Ph, J ¼ 7.2 Hz);
7.93 (d, 2H, Ph, J ¼ 7.2 Hz); 8.02 (d, 2H, Ph, J ¼ 7.2 Hz); 8.15 (d, 2H,
Ph, J ¼ 8.7 Hz); 11.63 (s, 1H, NH). MS m/z Calc. for C43H41N3O12:
791.82, found 790.25 [M  H].
4.1.1.2. Isomer (6f). Yield 167.2 mg (12%), m.p. 69e72 C,
[a]D25 þ 213.9 (c 0.018, CHCl3); 1H NMR (DMSO-d6): d 0.81 (t, 3H,
CH3, J ¼ 7.2 Hz); 1.19e1.26 (m, 6H, CH2); 1.42e1.50 (m, 2H, CH2);
3.23e3.45 (m, 2H, CH2); 4.62e4.68 (m, 2H, H-50); 4.73e4.78 (m,1H,
H-40); 5.33 (s, 1H, CH); 5.95e6.02 (m, 2H, H-20, H-30); 6.21 (d, 1H, H-
10, J¼ 3.6 Hz); 7.42e7.53 (m, 6H, Ph); 7.58e7.68 (m, 5H, Ph); 7.79 (s,
1H, Ph); 7.88e7.91 (m, 4H, Ph); 8.02 (d, 2H, Ph, J ¼ 6.9 Hz); 8.15 (d,
2H, Ph, J ¼ 8.7 Hz); 11.64 (s, 1H, NH). MS m/z Calc. for C43H41N3O12:
791.82, found 790.26 [M  H].
4.1.2. 20,30,50-tri-O-benzoyl-b-D-ribofuranosyl-5-[heptyl-(4-nitro-
phenyl)-methyl]-pyrimidine-2,4-dione (4g), (5g), (6g)
5-[Heptyl-(4-nitro-phenyl)-methyl]-1H-pyrimidine-2,4-dione
(3g) (600 mg, 1.6602 mmol) was heated in hexamethyldisilazane
(15 ml) at 140 C with (NH4)2SO4 (approximately 5 mg) for 8 h.
After that it was evaporated and residue was dissolved in
anhydrous 1,2-dichloroethane (20 ml). To this solution, 1-O-acetyl-
2,3,5-tri-O-benzoyl-b-D-ribofuranose (837.6 mg, 1.6603 mmol) and
trimethylsilyl trifluoro-methanesulfonate (331 ml, 1.8288 mmol)
were added. This mixture was stirred at room temperature for 2
days, washed with water (20 ml) and ethyl acetate (60 ml), dried
over sodium sulphate, filtered and evaporated to dryness. Yield of
crude product (4g) (mixture of diastereoisomers) 954.5 mg (71%).
Two diastereoisomers (5g) and (6g) were isolated in this order from
the mixture by silica gel column chromatography using methanol
in chloroform (0e5%).
4.1.2.1. Isomer (5g). Yield 372.7 mg (28%), m.p. 72e74 C,
[a]D25 þ 32.7 (c 0.11, CHCl3); 1H NMR (DMSO-d6): d 0.77e0.82 (m,
3H, CH3); 1.20e1.23 (m, 8H, CH2); 1.38e1.46 (m, 2H, CH2);
3.25e3.44 (m, 2H, CH2); 4.64e4.65 (m, 2H, H-50); 4.77e4.81 (m,1H,
H-40); 5.34 (s, 1H, CH); 5.94e6.01 (m, 2H, H-20, H-30); 6.25 (d, 1H, H-
10, J ¼ 4.5 Hz); 7.41e7.51 (m, 6H, Ph); 7.56e7.59 (m, 2H, Ph);
7.62e7.69 (m, 3H, Ph); 7.82e7.87 (m, 3H, Ph); 7.91e7.94 (m, 2H, Ph);
8.00e8.03 (m, 2H, Ph); 8.14 (d, 2H, Ph, J ¼ 9.0 Hz); 11.64 (s, 1H, NH).
MS m/z Calc. for C44H43N3O12: 805.85, found 804.25 [M  H].
4.1.2.2. Isomer (6g). Yield 361.5 mg (27%), m.p. 65e66 C,
[a]D25 þ 48.6 (c 0.074, CHCl3); 1H NMR (DMSO-d6): d 0.78e0.82 (m,
3H, CH3); 1.19e1.26 (m, 8H, CH2); 1.42e1.52 (m, 2H, CH2);
3.25e3.45 (m, 2H, CH2); 4.62e4.65 (m, 2H, H-50); 4.73e4.78 (m,1H,
H-40); 5.34 (s, 1H, CH); 5.95e6.02 (m, 2H, H-20, H-30); 6.21 (d, 1H, H-
10, J ¼ 3.9 Hz); 7.42e7.52 (m, 6H, Ph); 7.58e7.68 (m, 5H, Ph); 7.80 (s,
1H, Ph); 7.87e7.91 (m, 4H, Ph); 8.00e8.03 (m, 2H, Ph); 8.15 (d, 2H,
Ph, J ¼ 8.7 Hz); 11.64 (s, 1H, NH). MS m/z Calc. for C44H43N3O12:
805.85, found 804.25 [M  H].
4.1.3. 20,30,50-tri-O-benzoyl-b-D-ribofuranosyl-5-[oktyl-(4-nitro-
phenyl)-methyl]-pyrimidine-2,4-dione (4h), (5h), (6h)
5-[Oktyl-(4-nitro-phenyl)-methyl]-1H-pyrimidine-2,4-dione
(3h) (600 mg, 1.5982 mmol) was heated in hexamethyldisilazane
(15 ml) at 140 C with (NH4)2SO4 (approximately 5 mg) for 8 h.
After that it was evaporated and residue was dissolved in anhy-
drous 1,2-dichloroethane (20ml). To this solution,1-O-acetyl-2,3,5-
tri-O-benzoyl-b-D-ribofuranose (806.3 mg, 1.5982 mmol) and tri-
methylsilyl trifluoro-methanesulfonate (319 ml, 1.7625 mmol) were
added. This mixture was stirred at room temperature for 2 days,
washed with water (20 ml) and ethyl acetate (60 ml), dried over
sodium sulphate, filtered and evaporated to dryness. Yield of crude
product (4h) (mixture of diastereoisomers) 842.3 mg (67%). Two
diastereoisomers (5h) and (6h) were isolated in this order from the
mixture by silica gel column chromatography using methanol in
chloroform (0e5%).
Fig. 4. Cytotoxic activity of compounds 3fe3i, 7fe7i and 8fe8i as a function of chain
length in the A549 cell line.
Fig. 3. Cytotoxic activity of compounds 3fe3i, 7fe7i and 8fe8i as a function of chain
length in the K562-TAX cell line.
Fig. 5. Cytotoxic activity of compounds 3fe3i, 7fe7i and 8fe8i as a function of chain
length in CEM-DNR-B cell line.
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4.1.3.1. Isomer (5h). Yield 260.0 mg (21%), m.p. 69e70 C,
[a]D25 þ 38.5 (c 0.091, CHCl3); 1H NMR (DMSO-d6): d 0.81 (t, 3H, CH3,
J ¼ 7.2 Hz); 1.16e1.23 (m, 10H, CH2); 1.37e1.46 (m, 2H, CH2);
3.22e3.44 (m, 2H, CH2); 4.64e4.65 (m, 2H, H-50); 4.76e4.81 (m,1H,
H-40); 5.34 (s, 1H, CH); 5.94e6.01 (m, 2H, H-20, H-30); 6.25 (d,1H, H-
10, J ¼ 4.5 Hz); 7.41e7.51 (m, 6H, Ph); 7.57 (d, 2H, Ph, J ¼ 8.7 Hz);
7.62e7.68 (m, 3H, Ph); 7.82 (s, 1H, Ph); 7.86 (d, 2H, Ph, J ¼ 7.2 Hz);
7.93 (d, 2H, Ph, J ¼ 7.2 Hz); 8.02 (d, 2H, Ph, J ¼ 7.2 Hz); 8.14 (d, 2H,
Ph, J ¼ 8.7 Hz); 11.64 (s, 1H, NH). MS m/z Calc. for C45H45N3O12:
819.87, found 818.27[M  H].
4.1.3.2. Isomer (6h). Yield 205.0 mg (16%), m.p. 60e62 C,
[a]D25 þ 56.8 (c 0.059, CHCl3); 1H NMR (DMSO-d6): d 0.78e0.83 (m,
3H, CH3); 1.18e1.26 (m, 10H, CH2); 1.41e1.52 (m, 2H, CH2);
3.25e3.45 (m, 2H, CH2); 4.62e4.65 (m, 2H, H-50); 4.73e4.78 (m,1H,
H-40); 5.34 (s, 1H, CH); 5.95e6.02 (m, 2H, H-20, H-30); 6.22 (d,1H, H-
10, J¼ 3.6 Hz); 7.42e7.52 (m, 6H, Ph); 7.56e7.68 (m, 5H, Ph); 7.80 (s,
1H, Ph); 7.88e7.91 (m, 4H, Ph); 8.01 (d, 2H, Ph, J ¼ 7.5 Hz); 8.14 (d,
2H, Ph, J ¼ 8.7 Hz); 11.64 (s, 1H, NH). MS m/z Calc. for C45H45N3O12:
819.87, found 818.29 [M  H].
4.1.4. 20,30,50-tri-O-benzoyl-b-D-ribofuranosyl-5-[nonyl-(4-nitro-
phenyl)-methyl]-pyrimidine-2,4-dione (4i), (5i), (6i)
5-[Nonyl-(4-nitro-phenyl)-methyl]-1H-pyrimidine-2,4-dione
(3i) (600 mg, 1.5406 mmol) was heated in hexamethyldisilazane
(15 ml) at 140 C with (NH4)2SO4 (approximately 5 mg) for 8 h.
After that it was evaporated and residue was dissolved in anhy-
drous 1,2-dichloroethane (20ml). To this solution,1-O-acetyl-2,3,5-
tri-O-benzoyl-b-D-ribofuranose (777.2 mg, 1.5406 mmol) and tri-
methylsilyl trifluoro-methanesulfonate (307 ml, 1.6962 mmol) were
added. This mixture was stirred at room temperature for 2 days,
washed with water (20 ml) and ethyl acetate (60 ml), dried over
sodium sulphate, filtered and evaporated to dryness. Yield of crude
product (4i) (mixture of diastereoisomers) 721.3 mg (54%). Two
diastereoisomers (5i) and (6i) were isolated in this order from the
mixture by silica gel column chromatography using methanol in
chloroform (0e5%).
4.1.4.1. Isomer (5i). Yield 207.7 mg (16%), m.p. 62e63 C,
[a]D25 þ 90.2 (c 0.041, CHCl3); 1H NMR (DMSO-d6): d 0.82 (t, 3H, CH3,
J ¼ 6.9 Hz); 1.16e1.24 (m, 12H, CH2); 1.37e1.47 (m, 2H, CH2);
3.23e3.44 (m, 2H, CH2); 4.64e4.65 (m, 2H, H-50); 4.77e4.81 (m,1H,
H-40); 5.34 (s, 1H, CH); 5.94e6.01 (m, 2H, H-20, H-30); 6.26 (d, 1H, H-
10, J ¼ 4.5 Hz); 7.41e7.51 (m, 6H, Ph); 7.57 (d, 2H, Ph, J ¼ 8.7 Hz);
7.62e7.69 (m, 3H, Ph); 7.82e7.87 (m, 3H, Ph); 7.93 (d, 2H, Ph,
J ¼ 6.9 Hz); 8.02 (d, 2H, Ph, J ¼ 7.2 Hz); 8.14 (d, 2H, Ph, J ¼ 8.7 Hz);
11.64 (s, 1H, NH). MS m/z Calc. for C46H47N3O12: 833.90, found
832.39 [M  H].
4.1.4.2. Isomer (6i). Yield 213.2 mg (16%), m.p. 54e55 C,
[a]D25þ 56.4 (c 0.078, CHCl3); 1H NMR (DMSO-d6): d 0.81 (t, 3H, CH3,
J ¼ 6.9 Hz); 1.18e1.24 (m, 12H, CH2); 1.42e1.51 (m, 2H, CH2);
3.25e3.46 (m, 2H, CH2); 4.62e4.64 (m, 2H, H-50); 4.73e4.77 (m,1H,
H-40); 5.34 (s, 1H, CH); 5.95e6.02 (m, 2H, H-20, H-30); 6.22 (d,1H, H-
10, J ¼ 3.6 Hz); 7.42e7.52 (m, 6H, Ph); 7.58e7.68 (m, 5H, Ph); 7.80 (s,
1H, Ph); 7.87e7.91 (m, 4H, Ph); 8.01 (d, 2H, Ph, J ¼ 8.4 Hz); 8.14 (d,
2H, Ph, J ¼ 9.0 Hz); 11.64 (s, 1H, NH). MS m/z Calc. for C46H47N3O12:
833.90, found 832.40 [M  H].
4.1.5. General procedure for preparation of b-D-ribofuranosyl-5-
[alkoxy-(4-nitro-phenyl)-methyl]-pyrimidine-2,4-diones (7,8)
Nucleosides 5fe5i and 6fe6i were dissolved in MeOH/NH3
solution (7ml) and stirred at room temperature for 6 days. Then the
mixturewas evaporated, co-evaporatedwithmethanol and purified
by silica gel column chromatography using CHCl3/MeOH (9/0.5).
4.1.5.1. (þ)-b-D-ribofuranosyl-5-[hexyl-(4-nitro-phenyl)-methyl]-
pyrimidine-2,4-dione (7f). Nucleoside 7f was prepared from 5f
(171.8 mg, 0.2170 mmol) according to general procedure.
Yield 83.1 mg (80%), m.p. 72e74 C, [a]D25 þ 55.2 (c 0.077, CHCl3);
1H NMR (DMSO-d6): d 0.84 (t, 3H, CH3, J¼ 7.2 Hz); 1.23e1.35 (m, 6H,
CH2); 1.49e1.58 (m, 2H, CH2); 3.41e3.48 (m, 2H, CH2); 3.50e3.64
(m, 2H, H-50); 3.88e3.98 (m, 3H, H-20, H-30, H-40); 5.01 (t, 1H, 50-OH,
J¼ 4.8 Hz); 5.06 (d, 1H, 30-OH, J¼ 4.2 Hz); 5.35e5.38 (m, 2H, 20-OH,
CH); 5.78 (d, 1H, H-10, J ¼ 5.4 Hz); 7.62 (d, 2H, Ph, J ¼ 9.0 Hz); 7.98
(s,1H, Ph); 8.18 (d, 2H, Ph, J¼ 8.7 Hz); 11.44 (s,1H, NH). MSm/z Calc.
for C22H29N3O9: 479.49, found 478.21 [M  H].
4.1.5.2. ()-b-D-ribofuranosyl-5-[hexyl-(4-nitro-phenyl)-methyl]-
pyrimidine-2,4-dione (8f). Nucleoside 8f was prepared from 6f
(113.5 mg, 0.1433 mmol) according to general procedure.
Yield 60.1 mg (88%), m.p. 68e69 C, [a]D25  39.0 (c 0.39,
CHCl3); 1H NMR (DMSO-d6): d 0.84 (t, 3H, CH3, J ¼ 6.9 Hz);
1.25e1.36 (m, 6H, CH2); 1.49e1.58 (m, 2H, CH2); 3.42e3.50
(m, 2H, CH2); 3.52e3.56 (m, 2H, H-50); 3.84e3.86 (m, 1H, H-40);
3.95e3.99 (m, 1H, H-30); 4.02e4.08 (m, 1H, H-20); 5.02 (t, 1H,
Table 3











7h 200 100 100 200
7i 50 50 50 100
8h 200 100 100 200
8i 50 50 50 100
Table 2
Summary of conventional cell cycle, apoptosis, RNA/DNAe BrU/BrDU analysis of CEM leukemia cell line treated with standard anticancer drugs or themost potent compounds
7h, 7i and 8h, 8i. Data are expressed as a percentage of positive cells in the total cell population.
Compounds Apoptosis (%) G0/G1 (%) S (%) G2/M (%) BrUþ (%) BrDUþ (%) pH3Ser10þ (%)
Control 3 44.87 44.37 10.76 47.59 58.56 1.35
6-thioguanine 1 IC50 11.27 43.42 49.39 7.19 45.84 35.32 1.21
6-thioguanine 5 IC50 18.69 43.58 46.47 9.95 48.93 19.82 0.43
fludarabine 1 IC50 62.1 39.66 40.84 19.5 7.62 14.12 0.28
fludarabine 5 IC50 74.84 42.11 52.94 4.95 8.92 10.37 0.01
7h 1 IC50 7 42.36 47.81 9.83 58.1 46.03 2.05
7h 5 IC50 76 ND ND ND 1.44 6.01 0.03
7i 1 IC50 4 40.95 47.81 11.25 60.22 52.17 1.66
7i 5 IC50 83 ND ND ND 0.8 2.95 0.25
8h 1 IC50 5 40.02 48.56 11.33 56.18 48.73 1.68
8h 5 IC50 71 ND ND ND 1.61 6.67 0.01
8i 1 IC50 4 43.38 47.79 8.83 57.26 47.38 1.74
8i 5 IC50 83 ND ND ND 1.9 0.95 0.04
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50-OH, J ¼ 4.5 Hz); 5.10 (d, 1H, 30-OH, J ¼ 5.1 Hz); 5.39 (s, 1H, CH);
5.42 (d, 1H, 20-OH, J ¼ 5.4 Hz); 5.81 (d, 1H, H-10, J ¼ 5.1 Hz); 7.61
(d, 2H, Ph, J ¼ 8.7 Hz); 7.94 (s, 1H, Ph); 8.19 (d, 2H, Ph, J ¼ 8.7 Hz);
11.44 (s, 1H, NH). MS m/z Calc. for C22H29N3O9: 479.49, found
478.25 [M  H].
4.1.5.3. (þ)-b-D-ribofuranosyl-5-[heptyl-(4-nitro-phenyl)-methyl]-
pyrimidine-2,4-dione (7g). Nucleoside 7g was prepared from 5g
(207.6 mg, 0.2576 mmol) according to general procedure.
Yield 95.7 mg (75%), m.p. 63e65 C, [a]D25 þ 7.5 (c 0.30, CHCl3);
1H NMR (DMSO-d6): d 0.84 (t, 3H, CH3, J ¼ 7.2 Hz); 1.23e1.32
(m, 8H, CH2); 1.49e1.58 (m, 2H, CH2); 3.35e3.48 (m, 2H, CH2);
3.51e3.64 (m, 2H, H-50); 3.88e3.98 (m, 3H, H-20, H-30, H-40);
4.99e5.02 (m, 1H, 50-OH); 5.06 (bs, 1H, 30-OH); 5.35e5.38 (m, 2H,
20-OH, CH); 5.79 (d, 1H, H-10, J¼ 4.8 Hz); 7.63 (d, 2H, Ph, J¼ 8.7 Hz);
7.98 (s, 1H, Ph); 8.19 (d, 2H, Ph, J¼ 8.7 Hz); 11.44 (s, 1H, NH). MSm/z
Calc. for C23H31N3O9: 493.52, found 492.31 [M  H].
4.1.5.4. ()-b-D-ribofuranosyl-5-[heptyl-(4-nitro-phenyl)-methyl]-
pyrimidine-2,4-dione (8g). Nucleoside 8g was prepared from 6g
(232.4 mg, 0.2884 mmol) according to general procedure.
Yield 107.5 mg (76%), m.p. 71e72 C, [a]D25  40.0 (c 0.30, CHCl3);
1H NMR (DMSO-d6): d 0.84 (t, 3H, CH3, J ¼ 6.9 Hz); 1.23e1.32
(m, 8H, CH2); 1.50e1.59 (m, 2H, CH2); 3.47e3.52 (m, 2H, CH2);
3.54e3.60 (m, 2H, H-50); 3.84e3.87 (m, 1H, H-40); 3.95e3.99
(m, 1H, H-30); 4.02e4.08 (m, 1H, H-20); 5.00 (t, 1H, 50-OH,
J ¼ 4.8 Hz); 5.09 (d, 1H, 30-OH, J ¼ 4.8 Hz); 5.39e5.41 (m, 2H, CH,
20-OH); 5.80 (d,1H, H-10, J¼ 5.1 Hz); 7.62 (d, 2H, Ph, J¼ 8.7 Hz); 7.94
(s,1H, Ph); 8.19 (d, 2H, Ph, J¼ 8.7 Hz); 11.44 (s,1H, NH). MSm/z Calc.
for C23H31N3O9: 493.52, found 492.22 [M  H].
4.1.5.5. (þ)-b-D-ribofuranosyl-5-[oktyl-(4-nitro-phenyl)-methyl]-
pyrimidine-2,4-dione (7h). Nucleoside 7h was prepared from 5h
(228.3 mg, 0.2785 mmol) according to general procedure.
Yield 96.0 mg (68%), m.p. 67e69 C, [a]D25 þ 9.5 (c 0.32, CHCl3);
1H NMR (DMSO-d6): d 0.84 (t, 3H, CH3, J ¼ 7.2 Hz); 1.22e1.31
(m, 10H, CH2); 1.49e1.58 (m, 2H, CH2); 3.43e3.48 (m, 2H, CH2);
3.54e3.65 (m, 2H, H-50); 3.86e3.98 (m, 3H, H-20, H-30, H-40); 5.00
(t, 1H, 50-OH, J ¼ 5.1 Hz); 5.06 (m, 1H, 30-OH); 5.36 (d, 1H, 20-OH,
J¼ 5.1 Hz); 5.38 (s, 1H, CH); 5.78 (d,1H, H-10, J¼ 4.8 Hz); 7.63 (d, 2H,
Ph, J ¼ 8.7 Hz); 7.98 (s, 1H, Ph); 8.19 (d, 2H, Ph, J ¼ 8.7 Hz); 11.43
(s, 1H, NH). MS m/z Calc. for C24H33N3O9: 507.55, found 506.23
[M  H].
4.1.5.6. ()-b-D-ribofuranosyl-5-[oktyl-(4-nitro-phenyl)-methyl]-
pyrimidine-2,4-dione (8h). Nucleoside 8h was prepared from 6h
(175.0 mg, 0.2134 mmol) according to general procedure.
Yield 76.9 mg (71%), m.p. 62e64 C, [a]D25  36.0 (c 0.38, CHCl3);
1H NMR (DMSO-d6): d 0.84 (t, 3H, CH3, J ¼ 7.2 Hz); 1.23e1.32 (m,
10H, CH2); 1.49e1.57 (m, 2H, CH2); 3.42e3.49 (m, 2H, CH2);
3.52e3.56 (m, 2H, H-50); 3.83e3.87 (m,1H, H-40); 3.95e3.99 (m,1H,
H-30); 4.02e4.08 (m, 1H, H-20); 5.02 (t, 1H, 50-OH, J ¼ 4.5 Hz); 5.10
(d, 1H, 30-OH, J ¼ 4.8 Hz); 5.38 (s, 1H, CH); 5.41 (d, 1H, 20-OH,
J ¼ 5.1 Hz); 5.80 (d, 1H, H-10, J ¼ 5.1 Hz); 7.61 (d, 2H, Ph, J ¼ 8.7 Hz);
7.95 (s, 1H, Ph); 8.18 (d, 2H, Ph, J¼ 8.7 Hz); 11.44 (s, 1H, NH). MSm/z
Calc. for C24H33N3O9: 507.55, found 506.28 [M  H].
4.1.5.7. (þ)-b-D-ribofuranosyl-5-[nonyl-(4-nitro-phenyl)-methyl]-
pyrimidine-2,4-dione (7i). Nucleoside 7i was prepared from 5i
(180.7 mg, 0.2167 mmol) according to general procedure.
Yield 89.0 mg (79%), m.p. 62e64 C, [a]D25 þ 7.7 (c 0.26, CHCl3);
1H NMR (DMSO-d6): d 0.84 (t, 3H, CH3, J ¼ 6.9 Hz); 1.22e1.33 (m,
12H, CH2); 1.48e1.57 (m, 2H, CH2); 3.42e3.50 (m, 2H, CH2);
3.54e3.64 (m, 2H, H-50); 3.88e3.98 (m, 3H, H-20, H-30, H-40); 5.02
(t, 1H, 50-OH, J ¼ 4.8 Hz); 5.07 (d, 1H, 30-OH, J ¼ 4.5 Hz); 5.37e5.38
(m, 2H, 20-OH, CH); 5.77 (d, 1H, H-10, J ¼ 4.8 Hz); 7.62 (d, 2H, Ph,
J ¼ 8.7 Hz); 7.99 (s, 1H, Ph); 8.19 (d, 2H, Ph, J ¼ 8.7 Hz); 11.44 (s, 1H,
NH). MS m/z Calc. for C25H35N3O9: 521.57, found 520.30 [M  H].
4.1.5.8. ()-b-D-ribofuranosyl-5-[nonyl-(4-nitro-phenyl)-methyl]-
pyrimidine-2,4-dione (8i). Nucleoside 8i was prepared from 6i
(186.0 mg, 0.2230 mmol) according to general procedure.
Yield 84.4 mg (73%), m.p. 63e64 C, [a]D25  32.2 (c 0.38, CHCl3);
1H NMR (DMSO-d6): d 0.84 (t, 3H, CH3, J ¼ 6.9 Hz); 1.22e1.31
(m, 12H, CH2); 1.49e1.58 (m, 2H, CH2); 3.44e3.47 (m, 2H, CH2);
3.52e3.56 (m, 2H, H-50); 3.85e3.86 (m, 1H, H-40); 3.95e3.99
(m, 1H, H-30); 4.02e4.08 (m, 1H, H-20); 5.02 (t, 1H, 50-OH,
J ¼ 4.2 Hz); 5.10 (d, 1H, 30-OH, J ¼ 5.1 Hz); 5.38 (s, 1H, CH); 5.42
(d, 1H, 20-OH, J ¼ 5.7 Hz); 5.79 (d, 1H, H-10, J ¼ 5.1 Hz); 7.61 (d, 2H,
Ph, J ¼ 9.0 Hz); 7.94 (s, 1H, Ph); 8.19 (d, 2H, Ph, J ¼ 9.0 Hz); 11.43




CEM, A549, and K562 cell lines were purchased from the
American Tissue Culture Collection (ATTC). Paclitaxel/daunoru-
bicin resistant sublines of K562/CEM cells were prepared and
characterized in our laboratories. The human T-lymphoblastic
leukemia cell line, CEM, was used for routine screening of
compounds [19] The cells were maintained in Nunc/Corning
80 cm2 plastic tissue culture flasks and cultured in cell culture
medium (DMEM/RPMI 1640 with 5 g/L glucose, 2 mM glutamine,
100 U/mL penicillin, 100 mg/mL streptomycin, 10% fetal calf serum,
and NaHCO3).
4.2.2. Cytotoxicity assay
Cell suspensions were prepared and diluted according to the
particular cell type and the expected target cell density
(2500e30,000 cells/well based on cell growth characteristics). Cells
were added by pipette (80 mL) into 96-well microtiter plates.
Inoculates were allowed a pre-incubation period of 24 h at 37 C
and 5% CO2 for stabilisation. Four-fold dilutions, in 20-mL aliquots, of
the intended test concentration were added at time zero to the
microtiter plate wells.
All tested compounds were dissolved in 10% DMSO and
concentrations were examined in quadruplicate. Incubation of the
cells with the test compounds lasted for 72 h at 37 C, in a 5% CO2
atmosphere at 100% humidity. At the end of the incubation period,
the cells were assayed using MTT. Aliquots (10 mL) of theMTT stock
solution were pipetted into each well and incubated for a further
1e4 h. After this incubation period the formazan produced was
dissolved by the addition of 100 mL/well of 10% aq SDS (pH ¼ 5.5),
followed by a further incubation at 37 C overnight. The optical
density (OD) was measured at 540 nm with a Labsystem iEMS
Reader MF. Tumour cell inhibitory concentration (IC) was calcu-
lated using the following equation: IC ¼ (ODdrug-exposed well/mean
ODcontrol wells)  100%. The IC50 value, the drug concentration lethal
to 50% of the tumour cells, was calculated from appropriate dose-
response curves.
4.2.3. Apoptosis and cell cycle analysis by FACS
CEM cells were treated with appropriate compound at
concentrations corresponding to 1 and 5 IC50 values (107/
537 mM, 29/144 mM and 26/130 mM) for 3, 6, 9 and 24 h. Following
the incubation cells were pelleted, washed in PBS and fixed with
ice-cold 70% ethanol overnight at 20 C. Low molecular weight
apoptotic DNA was extracted in citrate buffer and RNAwas cleaved
by RNAse (0.5 mg/ml). The DNA was stained by propidium iodide
L. Brulíková et al. / European Journal of Medicinal Chemistry 45 (2010) 3588e3594 3593
(0.1 mg/ml), and the cells were analyzed by flow cytometry using
a 488 nm single beam laser (FACSCalibur, Becton Dickinson).
4.2.4. BrdU incorporation and cell cycle analysis [2]
CEM cells were treated with appropriate compound at
concentrations corresponding to 1 and 5 IC50 values (107/
537 mM, 29/144 mMand 26/130 mM) for 3, 6, 9 and 24 h. The cultures
were fed a pulse of 10 mM 5-bromo-20-deoxyuridine (BrdU) for
30 min at 37 C before harvesting. The cells were collected, washed
with PBS and fixed with ice-cold 70% ethanol overnight. Then cells
were washed with PBS, and resuspended in 2 M aq HCl for 30 min
at room temperature to denature their DNA. Following neutrali-
zation with 0.1 M Na2B4O7, pH 5, the cells were harvested by
centrifugation and washed with PBS containing 0.5% Tween-20 and
1% BSA. They were then stained with primary monoclonal anti-
BrdU antibody (1 mg/ml) (Exbio, s.r.o., Prague, Czech Republic) for
30 min at room temperature, following the incubation cells were
washed with PBS and stained for 30 min at room temperature with
the secondary mouse IgG-FITC antibody (4 mg/ml) (Sigma Chemical
Co., Prague, Czech Republic). The cells were then washed with
PBS, incubated with propidium iodide (0.1 mg/ml) and RNAse
A (0.5 mg/ml) for 1 h at room temperature in the dark and finally
analyzed by flow cytometry using a 488 nm single beam laser
(FACSCalibur, Becton Dickinson).
4.2.5. BrU incorporation, flow cytometric analysis of RNA synthesis
[3]
The cellular synthesis of RNA was analyzed by flow cytometry,
based on in vitro incorporation of the RNA precursor 50-bromour-
idine (BrU), followed by its immunocytochemical detection with
suitable cross reacting BrDU antibody. CEM cells were treated with
derivatives at concentrations corresponding to 1 and 5 IC50
values for 3, 6, 9 and 24 h. The cultures were fed a pulse of 10 mM
5-bromo-20-deoxyuridine (BrdU) for 30 min at 37 C before
harvesting. The cells were collected, washed with PBS and fixed
15 min with 1% paraformaldehyde, 0.05% NP-40 in PBS at room
temperature with rotation, the fixed cells were stored in the
paraformaldehyde solution at 4 C at least overnight before stain-
ing. Cells were washed once in cold 1% glycine in PBS to quench
autofluorescence and then once in PBS. They were then stained
with primary monoclonal anti-BrdU antibody (1 mg/ml) (Exbio, s.r.
o., Prague, Czech Republic) for 30 min at room temperature,
following the incubation cells were washed with PBS and stained
for 30 min at room temperature with the secondary mouse
IgG-FITC antibody (4 mg/ml) (Sigma Chemical Co., Prague, Czech
Republic). Then cells were fixed 15 min with 1% paraformaldehyde,
0.05% NP-40 in PBS at room temperature with rotation, washed
once in cold 1% glycine in PBS. The cells were then washed with
PBS, incubated with propidium iodide (0.1 mg/ml) and RNAse A
(0.5 mg/ml) for 1 h at room temperature in the dark and finally
analyzed by flow cytometry using a 488 nm single beam laser
(FACSCalibur, Becton Dickinson).
4.2.6. Antimicrobial activity
Antimicrobial activity was determined by the using of the
minimum inhibitory concentration as the lowest concentration of
the test substance that inhibited the growth of the bacterial strain
after incubation for 24h in a thermostat at 37 C.
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a b s t r a c t
Three pyrimidine nucleosides with differently substituted phenyltriazoles attached to the 5-position
were prepared by Cu(I)-assisted azide–alkyne cycloadditions (CuAAC) and incorporated into oligonucle-
otides. Efficient p–p-stacking between two or more phenyltriazoles in the major groove was found to
increase the thermal stability of a DNA:RNA duplex significantly. The best stacking, and most stable
duplex, was obtained by a sulfonamide substituted derivative.
 2010 Elsevier Ltd. All rights reserved.
1. Introduction
The nucleic acid duplex constitutes an excellent scaffold for
chemically designed supramolecular chemistry.1 The duplex is
formed between complementary oligonucleotide sequences on
the basis of selective hydrogen-bonding and strong p–p-stacking
of the nucleobases. With the aim of targeting RNA-sequences by
synthetic oligonucleotides, following the so-called antisense ap-
proach,2 the idea of synthetically increasing the stability of the du-
plex by increasing the stacking has been approached in several
ways including synthetic nucleobases with larger ring systems.3
A major example is a tricyclic phenoxazine replacing a cytosine
and increasing the thermal stability of a DNA:RNA duplex with
up to 5 C per modification.4 Furthermore, the 5-position of pyrim-
idine nucleosides has been functionalised with the propyn-1-yl
group5 as well as with five-membered heterocycles,6 and these
modifications have been found to increase the duplex stability
via increased p–p-stacking.
In our former study, we followed the concept of Click Chemis-
try7 and studied the Cu(I)-catalysed azide–alkyne cycloadditions
(CuAAC)8 performed on 5-ethynyl-20-deoxyuridine (1, Scheme 1).9 This
building block has been used for Click Chemistry conjugation of various
moieties to DNA10,11 and leads to the positioning of a triazole in the ma-
jor groove of the duplex. We found that one triazole, either unsubstitut-
ed or substituted with a phenyl or a benzyl group, in general leads to
decreased duplex stability, whereas four consecutive incorporations
lead to significant duplex stabilisation of a DNA:RNA duplex.9 Hence,
a 9-mer duplex with four triazoles in the centre (replacing the 5-methyl
groups of the bold thymidines in the duplex 50-dGTGTTTTGC:30-rCA-
CAAAACG) displayed an increase in melting temperature of 14 C as
compared to the unmodified duplex, and a further 7 C increase was
obtained by phenyl substituted triazoles (X in Scheme 1). Modelling
demonstrated (1) a clear preference for a coplanar orientation between
the pyrimidine and the triazole with the C5 of the triazole oriented to-
wards the O4 of the uracil (via a C–H  O interaction), and (2) a signif-
icant intrastrand p–p-stacking between the triazoles in the duplex
involving to some degree also the phenyl groups. In combination with
CD-spectroscopy, it was also shown that the duplexes are driven to-
wards A- or A/B-type like duplexes by the introduction of the p–p-
stacking triazoles.9
In the present study, we explore the scope of this stacking effect
of phenyltriazoles concerning (1) the degree of modification in the
duplex necessary to obtain the stabilisation, and (2) the effect of
hydrophilic substituents in combination with electron-donating
and withdrawing properties. We therefore decided to introduce a
phenol and a sulfonamide (Y and Z, respectively, Scheme 1). To
our best knowledge, this is at the same time the first introduction
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of a sulfonamide into DNA. Ultimately, these aromatic nucleosides
are extremely simple building blocks for the design of oligonucle-
otides with improved and selective hybridisation to complemen-
tary RNA and hereby an interesting potential in antisense
therapeutics.2
2. Results and discussion
2.1. Chemical synthesis
In our first study, we prepared the triazole containing pyrimi-
dine nucleosides directly from the unprotected 5-ethynyl-20-deox-
yuridine 1 using sodium azide, aryl or alkyl halides, and an in situ
azidation/cycloaddition protocol (Scheme 1).9 Each nucleoside,
including 2, was hereafter protected at the 50-position by the
4,40-dimethoxytrityl (DMT) group and converted to 30-O-phospho-
ramidites in order to afford building blocks suitable for incorpora-
tion into oligonucleotides using standard automated solid phase
DNA synthesis. By the phosphoramidite 3, oligonucleotides con-
taining the 5-(1-phenyl-1,2,3-triazol-4-yl)-20-deoxyuridine moiety
X were obtained.9 For the present study, we obtained the best re-
sults by performing the cycloaddition reactions on the 50-O-DMT-
protected 5-ethynyl-20-deoxyuridine 4 using azides that were pre-
pared and isolated from suitable building blocks (Scheme 2). For
introducing a phenol moiety, the protected azide 10 was prepared
by direct silylation of the known p-azidophenol 9, which has been
prepared from p-bromophenol.12 The TBDMS-group was chosen as
an appropriately base-sensitive protection for the phenol
group. For introducing a sulfonamide moiety, the known p-azido-
benzensulfonamide 11, made by a diazotation of p-aminobenzen-
sulfonamide,13 was protected with the equally base-sensitive
dimethylamidine group to give 12. The azides were reacted with
4 in the Cu(I)-catalysed cycloaddition to give the two protected
triazole nucleosides 5 and 6 in good yields (Scheme 1). These were
converted to the corresponding phophoramidites 7 and 8,
respectively.
The phosphoramidites 3, 7 and 8 were successfully incorpo-
rated into oligodeoxynucleotides using automated solid phase syn-
thesis with tetrazole as the activator and extended coupling times
for the modified phosphoramidites. After completion of the syn-
thesis, the oligonucleotides were removed from the solid support
by treatment with concentrated aqueous ammonia. This treatment
also removed all protecting groups including the silyl protection of
the phenol and the amidine protection of the sulfonamide giving
the incorporated monomers Y and Z, respectively, (Scheme 1).
The three monomers X, Y and Z were incorporated into the same
series of 9-mer oligonucleotides ON1–ON6 (Tables 1 and 2). The
constitution and purity of these were controlled by MALDI-MS
and RP-HPLC, respectively.
2.2. Hybridisation studies
The series of oligonucleotides for this study was chosen with
the purpose of finding the minimum of modification needed for
duplex stabilisation. Hence, the 9-mer oligonucleotides with one
and four incorporations of X in the centre, ON1 and ON6, were ta-
ken from our former study,9 whereas ON2–ON5 represent different
positions of a single modification as well as two or three consecu-
tive incorporations of X. The same series ON1–ON6 was hereafter
prepared with both Y and Z (Table 1).
The hybridisation studies of the oligonucleotides were per-
formed by UV-spectroscopy. For determining concentrations,
extinction coefficients for oligonucleotides were determined by
standard methods using extinction coefficients for the single
nucleotides. For the modified monomers X and Y, the extinction
coefficients at 260 nm for the deprotected phenyl9 and hydroxy-
phenyltriazole nucleosides were determined by UV-measure-
ments. Ab initio calculations of UV-spectra for a series of
derivatives of X indicated no increased absorption at 260 nm for
Z compared to X and therefore a similar extinction coefficient
was assumed. In order to secure a concentration of 1.5 lM for
the duplexes, however, a practical 50% lower coefficient for mono-
mer Z was applied in the hybridisation experiments.
The oligonucleotides were mixed with the complementary DNA
and RNA-sequences and the melting temperatures (Tm) of the
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Scheme 1. Reagents: (a) Ref. 9: PhBr, NaN3, CuI, Na ascorbate, EtOH, H2O, MW, 2
68%; (b) azide 10, CuI, Na ascorbate, pyridine, EtOH, H2O, 5 78%; (c) azide 12, CuSO4,
Na ascorbate, t-BuOH, H2O, THF, pyridine, 6 88%; (d) Ref. 9: (i) DMT–Cl, pyridine,
CH3CN; (ii) NC(CH2)2OPClN(iPr)2, EtN(iPr)2, CH2Cl2, 3 42%; (e) NC(CH2)2OPClN(iPr)2,
EtN(iPr)2, CH2Cl2, 7 74%, 8 67%; (f) automated DNA synthesis. DMT = 4,40-



















Scheme 2. Reagents: (a) TBDMS–Cl, DMAP, pyridine, CH3CN, 90%; (b) DMF, POCl3,
73%.
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obtained with modified DNA:DNA duplexes. A single incorporation
of either of the modified monomers X, Y or Z once in the centre of
the duplex, ON1, lead to a significant decrease in duplex stability as
validated by Tm’s around 5 C lower than for the unmodified du-
plex. The same was observed for ON2 although the decreases in
Tm were somewhat smaller. With the second incorporation of the
modified monomers, in ON3 and ON4, the relative destabilisation
was even less pronounced, especially in the case of the sulfon-
amide Z (DTm = 0.8 C per mod.). The same trend continued with
three incorporations, ON5, and with four modified nucleoside
monomers, ON6, the decrease in duplex stability was fully com-
pensated by the stacking of the modified nucleobases. Hence, the
duplex stabilities were similar to the unmodified duplex, varying
from a small decrease with the phenol Y (DTm = 1.0 C per
mod.) to a small increase with the sulfonamide Z (DTm = +0.7 C
per mod.).
Table 2 shows the hybridisation data of the modified DNA:R-
NA duplexes. A single incorporation of either X, Y or Z, in ON1
or ON2, lead to decreases in thermal stability that were some-
what smaller than with DNA:DNA (DTm’s between 0.5 and
2.0 C). This picture changed significantly by the introduction
of the second modified nucleoside. ON3 displayed significantly
increased duplex stabilities, and in the slightly different se-
quence ON4, even further increases were observed with DTm’s
up to +4 C per modification. The tendency continued by three
and four incorporations in ON5 and ON6 revealing further rela-
tive increases in duplex stability with DTm’s up to +6.1 C per
modification for the four sulfonamide substituted phenyltriazoles
Z. Interestingly, the hyperchromicity observed for the melting of
a duplex generally decreased by the numbers of monomer Z but
not in the case of monomers X and Y. Nevertheless, the melting
transitions were clearly determined.
Comparing the data for the modified DNA:RNA duplexes in a
different way, the introduction of the second phenyltriazole moi-
ety on the top of the first gave an increase in Tm of 5 C (compare
ON3 with ON2, Table 2) or even 8.5 C (compare ON4 with ON1)
for X. The third incorporation of X gave an increase in Tm of 5.5
or 8 C (compare ON5 with ON3 or ON4), and the fourth incorpora-
tion of X gave a further increase in Tm of 8.5 C (compare ON6 with
ON5). The corresponding increases in Tm for the phenol moiety Y
were +8/8.5 for the second, +6/+8 C for the third and +6 C for
the fourth incorporation. For the sulfonamide Z, the increases in
Tm were +6.5/9 for the second, +7/+10.5 C for the third and
+9.5 C for the fourth incorporation.
The remarkable RNA recognition was further investigated by
mismatch studies. Hence, ON6 with either X, Y or Z was mixed
with RNA-sequences containing a single central mismatch, and
the melting temperatures of the mismatched duplexes were deter-
mined (Table 2). In most cases, fine mismatch discrimination was
observed as indicated by the large decreases in Tm relative to the
matched duplexes formed by ON6. A to C mismatches were per-
fectly discriminated by X and Y (DTm values of 27.5 and
24.5 C, respectively), whereas no mismatched duplex by Z could
be detected. Similar results were observed for the A to U mis-
matches, whereas the discrimination of the A to G mismatches
was slightly smaller for all the three modifications X–Z (DTm’s
around 10 C). This is however similar to unmodified DNA:RNA
duplexes, where the A to G mismatch is the most stable of the
three.
The fact that two mismatched duplexes formed by ON6-Z were
not detectable by UV-spectroscopy was puzzling but seemed asso-
ciated with the generally low hyperchromicity observed for the
DNA:RNA duplexes with Z. With the local denaturation induced
in the middle of the duplex by a mismatch the transition might
be undetectable by the UV-methodology.
2.3. Circular dichroism spectroscopy
To further study the influence of p–p-stacking and the stepwise
increasing modification on the duplex structure, circular dichroism
(CD) spectroscopy was applied. It is well known that DNA:DNA du-
plexes adopt a B-type form in solution, whereas RNA:RNA duplexes
adopt an A-type and DNA:RNA duplexes intermediate A/B-type
structures. A- and B-type duplexes are known to display distinctly
different CD spectra. A-type duplexes give an intense negative
band at 210 nm and a positive band at 260 nm, whereas B-type
Table 1
Hybridisation data for DNA:DNA duplexesa
Tm (DTm/mod.)/(C)b
B = X Y Z




































a Target sequence 50-dGCA AAA CAC.
b Melting temperatures (Tm values/C) obtained from the maxima of the first
derivatives of the melting curves (A260 vs temperature) recorded in a medium salt
buffer (Na2HPO4 (5 mM), NaCl (100 mM), EDTA (0.1 mM), pH 7.0) using 1.5 lM
concentrations of each strand. In brackets the changes in melting temperature for
each modification B (DTm/mod./C) as compared to the unmodified reference
duplex (Tm = 33.0 C).
c Data taken from Ref. 9.
Table 2
Hybridisation data for DNA:RNA duplexesa
Tm (DTm/mod.)/Cb
B = X Y Z



























































a Matched target sequence 50-rGCA AAA CAC.
b Melting temperatures (Tm values/C) obtained from the maxima of the first
derivatives of the melting curves (A260 vs temperature) recorded in a medium salt
buffer (Na2HPO4 (5 mM), NaCl (100 mM), EDTA (0.1 mM), pH 7.0) using 1.5 lM
concentrations of each strand. In brackets the changes in melting temperature for
each modification B (DTm/mod./C) as compared to the unmodified reference
duplex (Tm = 31.0 C).
c Data taken from Ref. 9.
d Mismatch studies, in brackets the changes in melting temperature as compared
to the matched duplex ON6:RNA.
e No transition observed.
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duplexes give a negative band at 250 nm and positive bands at
220 and 280 nm. For this study the unmodified DNA:DNA du-
plex was taken as a standard for the B-type, and the CD-spectrum
(Fig. 1) clearly displayed the B-type characteristics. The DNA:RNA
duplex showed the expected intermediate A/B-type with some
clear A-type characteristics. The single incorporation of monomer
X in ON2 indicated that the DNA:DNA duplex retained its inherent
B-type form (Fig. 1). This is similar to what was observed for ON1-
X in our first study.9 However, the double incorporation of X in
ON3 and ON4 resulted in two slightly different CD-curves. ON3
resembled ON2, whereas ON4 showed a small shift of the band
at 280 nm towards 275 nm. Upon the triple incorporation of X in
ON5 we observed a further small shift towards the A/B-type helical
form with a beginning shoulder at 265 nm and a decreasing nega-
tive band at 250 nm. This is fully in accordance with our previous
observations for ON6-X.9
For the DNA:RNA hybrid duplex, only small changes in the CD-
spectra were observed by the introduction of X (Fig. 2). Hence, all
curves were similar to the one obtained from the unmodified
DNA:RNA duplex indicating that the modifications are not chang-
ing the overall A/B-type duplex structure. This is consistent with
our first study where both ON1-X and ON6-X displayed similar
CD-curves with RNA.9
In the case of the sulfonamide modification Z, the CD-curves
revealed somewhat different observations. For the DNA:DNA du-
plex, the single modification in ON1 demonstrated almost no
changes in the CD-spectrum, whereas the spectrum for ON2
demonstrated a lower band at 280 nm and a beginning shoulder
at 265 nm (Fig. 3). With the two modifications in ON3 and ON4,
this trend continued with the largest changes observed for ON3.
In other works, both the number of modifications and the se-
quence context influenced the gradual change in duplex struc-
ture. With the three modifications in ON5, an even larger band
at 265 nm was seen indicating the expected shift towards an
A/B-type duplex but also other changes in the CD curve were
seen. With ON6, the positive band has moved backwards to
275 nm, and the negative band at 250 nm has become very
small.
For the DNA:RNA duplexes containing the sulfonamide Z, all
CD-spectra indicated that the modified duplexes had an A/B-type
hybrid duplex conformation not differing significantly from the
unmodified DNA:RNA duplex (Fig. 4). With the increasing number
of modifications, however, the intensity of the negative band at
250 nm was decreasing and moving towards 235 nm, and a new
small positive band appeared at 310 nm.
2.4. Molecular modelling
The DNA:RNA hybrid duplexes formed by the oligonucleotides
with two and four consecutive incorporations of monomer X, Y
and Z (ON3 and ON6) were built in MACROMODEL14 and studied
in molecular dynamics simulations. The initial hybrid structures
were built in the B-type duplex conformation and the incorpo-
rated monomers were subjected to a Monte Carlo conforma-
tional search verifying the C5 (pyrimidine)–C4 (triazole) bond
previously studied via ab initio calculations.9 The obtained low-
est energy structure was then subjected to a 5 ns molecular
dynamics simulation during which 500 structures were sampled.
These 500 structures were subsequently minimised, and the lo-
cal minimum structure obtained was used for further analysis.
Models of the resulting modified duplexes are shown in Figures
5 and 6.
The DNA:RNA duplexes with four consecutive incorporations of
either X,9 Y and Z (Fig. 5) were found to be A/B-type duplexes with
almost perfect stacking between both triazoles and phenyl moie-
ties. However, some differences were observed. In the duplex with
the phenol moieties Y, the aromatic rings seems to bend slightly
away towards the 50-end, perhaps from a repulsion between the
hydroxy groups. The duplex with the sulfonamide monomer Z,
on the other hand, demonstrated a perfect stacking of the aromatic
rings and apparently a consistent organisation between the neigh-
bouring sulfonamide groups. Furthermore, some distortion in the
duplex inclination was observed in all three cases but most pro-
nounced with Z. Thus, a short 2.8 Å distance consistent with hydro-
gen-bonding was observed between the second sulfonamide group
from the 50-end in ON6-Z and the 20-hydroxyl group of the 50-ter-
minal cytosine in the complementary RNA strand. This seemed to
be forcing the duplex to bend, although, the Watson–Crick base
pairing was conserved.
Also the DNA:RNA duplexes with two consecutive incorpora-
tions of either X, Y and Z (Fig. 6) were found to be A/B-type du-
plexes. Stacking between the aromatic systems are observed in
Figure 1. CD spectra of the DNA:DNA duplexes containing one to three incorporations of X.
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all three cases, although the two modified nucleobases were tilted
out of the nucleobase plane pointing towards the 30-end of the
strand. This is less pronounced with the two monomers X but in
the 30-modification of the two, the co-planarity between the two
heterocycles appeared to be lost. For monomer Y, this tilting of
the modifications towards the 30-end was even more pronounced,
although no changes in the co-planarity were observed. An almost
similar structure is seen with monomer Z.
3. Discussion
In the present study we have demonstrated the simple and effi-
cient synthesis of two new nucleoside building blocks following
the CuAAC method. Clearly, 5-ethynyl-20-deoxyuridine, 1, consti-
tutes an obvious substrate for the easy preparation of various tria-
zoles, and click chemistry is hereby a convenient method for
introducing aromatic stacking in the major groove of nucleic acid
duplexes.
The hybridisation data for the oligonucleotides of the current
study followed the trend of our first study demonstrating that
one incorporation of X lead to decreased stability of both
DNA:DNA and DNA:RNA duplexes, whereas four consecutive
incorporations of X demonstrate a net neutral effect on the sta-
bility of the DNA:DNA duplex and a massive increase in stability
of the DNA:RNA duplex. Herein, we have demonstrated that the
increase in duplex stability graduates by the number of modifi-
cations, and that two incorporations were enough to see the ma-
jor part of the effect. The reason for the significant decrease in
duplex stability obtained with single modifications with X might
be found in the hydrophobicity of the phenyl group and the
distortion in hydration of the duplex. This can, however, be
Figure 2. CD spectra of the DNA:RNA duplexes containing one to three incorporations of X.
Figure 3. CD spectra of the DNA:DNA duplexes containing one to four incorporations of Z.
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completely counterbalanced by the stacking of two phenyltriaz-
ole moieties as indicated by the very large increase in thermal
stability of DNA:RNA duplexes when going from ON1 and ON2
to ON3 and ON4. Also in the DNA:DNA duplexes some compen-
sation by the second modification was clearly seen. The third
and fourth consecutive incorporation of X lead to further relative
increase in stabilisation up to an increase in thermal stability of
the DNA:RNA duplex of 5 C for each modification. The observa-
tion that only two consecutive incorporations of X were enough
to give significant duplex stabilisation is very important for prac-
tical RNA-targeting, as the number of possible target sequences
increases dramatically. Future studies will show, whether tria-
zoles attached to other nucleobases can demonstrate the same
duplex stabilisation by stacking with X hereby open the access
to even more potential target RNA-sequences.
The two new derivatives Y and Z displayed almost similar influ-
ence on duplex stability as X indicating only small influence from
the substituents on the distal phenyl position. In the DNA:DNA du-
plexes, the phenol Y seems to give the largest decreases in duplex
stability, whereas the partial compensation obtained with consec-
utive incorporations seems to be most pronounced with the sul-
fonamide Z. In the DNA:RNA duplexes, the only obvious
difference between X, Y and Z was that the stabilising effect of
stacking three or four building blocks is even more pronounced
with Z ending with the most stable duplex of the entire study with
a Tm of 55.5 C corresponding to a gain in thermal stability of
+6.1 C per modification.
When considering duplex structures as studied by modelling
and CD-spectroscopy, some differences between the three modifi-
cations were indicated supporting the hybridisation data. The sul-
fonamide modification Z seems to have the largest impact on
duplex structure of the three, probably due to the most efficient
stacking behaviour. The modelling data indicated some bending
of the DNA:RNA duplex with 4  Z due to a hydrogen-bonding
interaction across the major groove, and the CD-spectrum sup-
ported some deviation from the standard A/B-type duplex.
The current study demonstrated the value of p–p-stacking for
obtaining duplexes with increased thermal stability. The effect of
stacking was strongest in the DNA:RNA duplexes as compared to
DNA:DNA duplexes, which might be due to the A/B-type duplex
form being shorter and more compact than the B-type duplex. In
the modified DNA:DNA, the increasing number of modifications
and hereby the increasing stacking in the major groove was fol-
lowed by a shift in duplex structure towards an A/B-type form as
demonstrated by CD-spectroscopy. In the DNA:RNA duplex, the
A/B-type was more or less retained when the modifications were
introduced.
With the specific goal of targeting RNA, oligonucleotides con-
taining enlarged bi- or tricyclic nucleobases or aromatic substitu-
ents on the nucleobases have been approached before.4,6 In the
case of the phenoxazine cytosine analogue, increased effect by
the number of consecutive incorporations due to stacking in
the major groove has also been demonstrated.4 Nevertheless,
the nucleoside monomers X, Y and Z from the current study
demonstrates that this stacking effect can be obtained with sim-
pler aromatic moieties obtained by straightforward click chemis-
try. This simple approach opens the possibility for a large
variation of different entities in the major groove and with a
much wider range of potential target sequences. The 5-(1,2,3-tri-
azole-4-yl)pyrimidine nucleosides can therefore be important fu-
ture building blocks for the development of antisense
oligonucleotides.
4. Conclusions
From the easily available 5-ethynyl-20-deoxyuridine, three sim-
ple nucleic acid building blocks introducing triazoles into the ma-
jor groove of nucleic acid duplexes have been obtained. The
stacking of triazoles, and the aromatic substituents attached, in
the major groove leads to very stable DNA:RNA duplexes—the
most stable containing a distal sulfonamide moiety. Efficient
RNA-targeting, and hereby therapeutic potential, can be obtained
with oligonucleotides containing only two consecutive incorpora-
tions of the triazoles.
5. Experimental section
All commercial reagents were used as supplied. Reactions
were carried out under argon or nitrogen when anhydrous sol-
vents were used. Column chromatography was performed with
Silica Gel 60 (particle size 0.040–0.063 lm, Merck). NMR spectra
Figure 4. CD spectra of the DNA:RNA duplexes containing one to four incorporations of Z.
N. K. Andersen et al. / Bioorg. Med. Chem. 18 (2010) 4702–4710 4707
were recorded on a Varian Gemini 2000 spectrometer or a Bru-
ker Advance III 400 spectrometer. Values for d are in ppm rela-
tive to tetramethylsilane as an internal standard or 85% H3PO4 as
an external standard. Assignments of NMR-signals when given
are based on 2D spectra and follow standard nucleoside conven-
tion. ESI mass spectra as well as accurate mass determinations
were performed on a Thermo Finnigan TSQ 700 spectrometer.
Microwave heated reactions were performed on an Emrys™
Creator.
5.1. Synthesis of 5-(1-(4-(tert-butyldimethylsilyloxy)phenyl)-
1,2,3-triazol-4-yl)-50-(4,40-dimethoxytrityl)-20-deoxyuridine (5)
To a solution of nucleoside 4 (485 mg, 0.88 mmol) and the azide
10 in ethanol and water (10 mL, 7:3, v/v) was added CuI (108 mg,
0.57 mmol), sodium ascorbate (281 mg, 1.42 mmol) and pyridine
(3 mL). The mixture was stirred at rt for 4.5 h and then concen-
trated under reduced pressure. The residue was co-evaporated
with toluene (2  10 mL), and methanol (10 mL), and then purified
by column chromatography (0–10% CH3OH in CH2Cl2) to give the
nucleoside 5 (550 mg, 78%) as a white foam. Rf 0.3 (5% MeOH in
CH2Cl2). 1H NMR (DMSO-d6; 300 MHz) d 11.81 (s, 1H, NH), 8.72
(s, 1H, triazole-H), 8.40 (s, 1H, H-6), 7.77 (d, 2H, J = 8.9 Hz, Ar),
7.39 (m, 2H, Ar), 7.29–7.21 (m, 6H, Ar), 7.15 (m, 1H, Ar), 7.04 (d,
2H, J = 8.9 Hz, Ar), 6.82 (dd, 4H, J = 8.7, 1.5 Hz, Ar), 6.21 (t, 1H,
J = 6.3 Hz, H-10), 5.37 (d, 1H, J = 4.5 Hz, 30-OH), 4.23 (m, 1H, H-30),
3.98 (m, 1H, H-40), 3.68 (s, 3H, OCH3), 3.67 (s, 3H, OCH3), 3.25–
3.22 (m, 2H, H-50), 2.33–2.27 (m, 2H, H-20), 0.98 (s, 9H, (CH3)3C),
0.24 (s, 6H, (CH3)2Si). 13C NMR (DMSO-d6; 75 MHz) d 161.1 (C-4),
158.0, 155.3 (Ar), 149.7 (C-2), 149.4, 144.8 (Ar), 136.2, 135.5,
135.4 (C-6, Ar), 130.7 (C-4 triazole), 129.7, 129.6, 127.7, 127.6,
126.5, 121.9, 120.8 (Ar), 120.1 (C-5 triazole), 113.1 (Ar), 104.8 (C-
5), 85.7 (C-40), 85.7 (Ar3C), 85.3 (C-10), 70.4 (C-30), 63.6 (C-50),
54.9 (OCH3), 39.5 (C-20), 25.5 ((CH3)3C), 17.9 ((CH3)3C), 4.6
Figure 5. Modelling structures of modified DNA:RNA duplexes containing four consecutive incorporations of X, Y or Z. From left to right: ON6-X:RNA, ON6-Y:RNA, ON6-
Z:RNA. Blue: 5-substituents with the heteroatoms in light blue; red: backbone; green: nucleobases.
Figure 6. Modelling structures of modified DNA:RNA duplexes containing two consecutive incorporations of X, Y or Z. From left to right: ON3-X:RNA, ON3-Y:RNA, ON3-
Z:RNA. Blue: 5-substituents with the heteroatoms in light blue; red: backbone; green: nucleobases.
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((CH3)2Si). HiRes ESI MS m/z (M+Na) found/calcd 826.3213/
826.3243.
5.2. Synthesis of 5-(1-(4-(N-((dimethylamino)methylidene)
aminosulfonyl)phenyl)-1,2,3-triazol-4-yl)-50-(4,40-dimetho-
xytrityl)-20-deoxyuridine (6)
To a suspension of the nucleoside 4 (300 mg, 0.54 mmol), the
azide 12 (178 mg, 0.70 mmol), sodium ascorbate (65 mg,
0.32 mmol) and CuSO45H2O (25 mg, 0.1 mmol) in H2O/t-BuOH
(8 mL, 1:1, v/v) was added THF (1 mL) and pyridine (0.25 mL).
The resulting clear solution was stirred at rt for 14 h, and then di-
luted with CH2Cl2 (50 mL) and brine (30 mL). The phases were
separated, and the organic phase was washed with a saturated
aqueous solution of NaHCO3 (30 mL). The combined aqueous
phase was extracted with EtOAc (2  30 mL), and the combined
organic phase was dried (Na2SO4), and concentrated under re-
duced pressure. The residue was purified by column chromatog-
raphy (0–8% MeOH in CH2Cl2) to afford the nucleoside 6
(220 mg, 87%) as a white foam. Rf 0.3 (5% i-PrOH in CHCl3). 1H
NMR (CDCl3, 400 MHz) d 8.70 (br s, 1H, NH), 8.55 (br s, 1H,
HC@N), 8.17 (s, 1H, triazole-H), 8.06 (m, 2H, Ar), 7.90 (d, 2H,
J = 8.0 Hz, Ar), 7.40 (d, 2H, J = 7.6 Hz, Ar), 7.33–7.12 (m, 8H, Ar,
H-6), 6.82 (m, 4H, Ar), 6.32 (t, 1H, J = 6.0 Hz, H-10), 4.45 (br s,
1H, H-30), 4.07 (m, 1H, H-40), 3.74 (s, 6H, OCH3), 3.45–3.29 (m,
2H, H-50), 3.16 (s, 3H, CH3), 3.05 (s, 3H, CH3), 2.48 (m, 1H, H-
20), 2.31 (m, 1H, H-20). 13C NMR (CDCl3, 100 MHz) d 160.9,
158.58, 158.56, 144.6, 142.4, 135.7, 135.6, 130.1, 130.1, 128.3,
128.1, 127.9, 126.9, 120.2, 113.3, 86.9, 85.9, 77.2, 72.5, 63.6,
55.2, 41.6, 35.7. HiRes ESI MS m/z (M+Na) found/calcd
830.2610/830.2578.
5.3. Synthesis of 5-(1-(4-(tert-butyldimethylsilyloxy)phenyl)-
1,2,3-triazol-4-yl)-50-(4,4-dimethoxytrityl)-30-O-(P-(2-cyanoe-
thoxy)-N,N-diisopropylaminophosphinyl)-20-deoxyuridine (7)
The nucleoside 5 (213 mg, 0.26 mmol) was dried by the co-
evaporation with anhydrous CH2Cl2 (2  5 mL) and dissolved in
anhydrous CH2Cl2 (5.5 mL). DIPEA (0.23 mL, 1.33 mmol) and 2-cya-
noethyl-N,N0-diisopropyl-phosphoramidochloridite (177 lL,
0.79 mmol) were added, and the mixture was stirred at rt for 1 h,
15 min. The solution was diluted with CH2Cl2 (25 mL) and washed
with brine (25 mL) and water (25 mL). The organic phase was dried
(Na2SO4) and concentrated under reduced pressure. The residue
was purified by column chromatography (2–5% acetone in CH2Cl2)
to give the product 7 (196 mg, 74%) as a white foam. Rf 0.8 (10%
acetone in CH2Cl2). 31P NMR (DMSO-d6, 121.5 MHz) d 148.6,
148.3. HiRes ESI MS m/z (M+Na) found/calcd 1026.4308/
1026.4321).




The nucleoside 6 (300 mg, 0.37 mmol) was dried by the co-
evaporation with anhydrous CH2Cl2 (2  10 mL) and dissolved in
anhydrous CH2Cl2 (10 mL). DIPEA (0.25 mL, 1.4 mmol) and 2-cya-
noethyl-N,N0-diisopropyl-phosphoramidochloridite (0.25 mL,
1.1 mmol) were added, and the reaction mixture was stirred at rt
for 4 h. The solution was diluted with CH2Cl2 (25 ml) and washed
with a 5% aqueous solution of NaHCO3 (2  10 mL). The aqueous
phase was extracted with CH2Cl2 (2  10 mL) and the combined or-
ganic phase was dried (Na2SO4) and concentrated under reduced
pressure. The residue was purified by column chromatography
(0–96% EtOAc in petroleum ether) to give the phosphoramidite 8
(250 mg, 67%) as a white foam. Rf 0.5 (7.5% i-PrOH in CHCl3). 31P
NMR (CDCl3, 162 MHz) d 149.1, 148.7. HiRes ESI MS m/z (M+Na)
found/calcd 1030.3629/1030.3657.
5.5. Synthesis of tert-butyldimethylsilyl 4-azidophenylether (10)
A solution of the azide 9 (1.12 g, 8.27 mmol), tert-butyldimeth-
ylsilyl chloride (3.74 g, 24.8 mmol) and DMAP (0.5 g, 4.09 mmol) in
a mixture of pyridine and acetonitrile (32 mL, 1:1, v/v) was stirred
at rt for 48 h. The mixture was concentrated under reduced pres-
sure and the residue was co-evaporated with toluene (2  20 mL)
and methanol (10 mL). The residue was purified by column chro-
matography (CH2Cl2) to give the azide 10 (1.86 g, 90%) as a yellow
liquid. Rf 0.9 (CH2Cl2). IR (KBr) 2122.4 cm1. 1H NMR (DMSO-d6,
300 MHz) d 7.01 (m, 2H, Ar), 6.89 (m, 2H, Ar), 0.94 (s, 9H,
(CH3)3C), 0.17 (s, 6H, (CH3)2Si). 13C NMR (DMSO-d6, 75 MHz) d
152.5, 132.3, 121.2, 120.2 (Ar), 25.5 ((CH3)3C), 17.9 ((CH3)3C),
4.7 ((CH3)2Si). HiRes ESI MS m/z (M+Na) found/calcd 272.1184/
272.1190.
5.6. Synthesis of N-dimethylaminomethylidene-4-azidobenzene-
sulfonamide (12)
To a cold stirred solution of POCl3 (0.98 mL, 10.6 mmol) in
dimethylformamide (20 mL) was added the azide 11 (1.05 g,
5.30 mmol). The reaction mixture was stirred at rt for 3 h, and then
poured into cold water and neutralised with saturated aqueous
ammonia. The formed precipitate was isolated, washed with water
(100 mL) and dried to afford the product 12 (0.98 g, 73%) as white
solid. Rf 0.4 (40% EtOAc in petroleum ether). Mp 155–156 C. 1H
NMR (DMSO-d6, 400 MHz) d 8.21 (s, 1H, HC@N), 7.78 (d, 2H,
J = 8.4 Hz, Ar), 7.24 (d, 2H, J = 8.4 Hz, Ar), 3.14 (s, 3H, CH3), 2.90
(s, 3H, CH3). 13C NMR (DMSO-d6, 100 MHz) d 159.7, 142.8, 139.4,
127.8, 119.4 (Ar, C@N), 40.8, 35.0 (CH3).
5.7. Synthesis of oligodeoxynucleotides
Oligonucleotide synthesis was carried out on an automated
DNA synthesiser following the phosphoramidite approach. Synthe-
sis of oligonucleotides ON1–ON6 (X–Z) was performed on a
0.2 lmol scale by using the amidites 3, 7 and 8 as well as the cor-
responding commercial 2-cyanoethyl phosphoramidites of the nat-
ural 20-deoxynucleosides. The synthesis followed the regular
protocol for the DNA synthesiser. For compound 3, 7 and 8, a pro-
longed coupling time of 20 min was used. 1H-Tetrazole was used
as the activator and coupling yields for all 2-cyanoethyl phospho-
ramidites were 95–99.8%. The 50-O-DMT-ON oligonucleotides were
removed from the solid support by treatment with concentrated
aqueous ammonia at 55 C for 16 h, which also removed the pro-
tecting groups. The oligonucleotides were purified by reversed-
phase HPLC on a Waters 600 system using a Xterra prep MS C18;
10 lm; 7.8  150 mm column; buffer A: 0,05 M triethyl ammo-
nium acetate pH 7.4. Buffer B: MeCN/H2O (1:1). Program used:
2 min 100% A, 100–30% A over 38 min, 10 min 100% B, 10 min
100% A. All oligonucleotides were detritylated by treatment with
an 80% aqueous solution of acetic acid for 20 min, quenched with
a aqueous solution of sodium acetate (3 M, 15 lL) and then added
sodium perchlorate (5 M, 15 lL) followed by acetone (1 mL). The
pure oligonucleotides precipitated overnight at 20 C. After cen-
trifugation 12,000 rpm, 10 min at 4 C, the supernatant was re-
moved and the pellet washed with cold acetone (2  1 mL) and
dried for 30 min under reduced pressure, and dissolved in pure
water (500 lL). The concentration was determined by UV at
260 nm, and the purity confirmed by IC analysis. MALDI-TOF-MS
[MH] gave the following results (calcd/found): ON2-X (2864.9/
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2865.4); ON3-X (2994.0/2992.0); ON4-X (2994.0/ 2995.3); ON5-X
(3124.5/3123.9); ON1-Y (2880.9/2878.0); ON2-Y (2881.3/2876.5);
ON3-Y (3026.9/3024.7); ON4-Y (3026.0/3024.1); ON5-Y (3173.0/
3171.7); ON6-Y (3316.0/ 3315.8); ON1-Z (2943.0/2941.8); ON2-Z
(2943.0/2943.5); ON3-Z (3151.0/3146.0); ON4-Z (3151.0/)3147.0;
ON5-Z (3526.8/3522.4); ON6-Z (3567.0/3567.0).
5.8. Thermal denaturation experiments
Extinction coefficients of the modified oligonucleotides were
estimated from a standard method but calibrated by the micromo-
lar extinction coefficients of the monomeric compounds X, Y and
dT, which were estimated from their UV-spectra (dT: e260 = 8.5,
X: e260 = 7.8, Y: e260 = 12.6), and Z, which was estimated by ab ini-
tio calculated oscillator strength to be e260  8.0; practically we
used a e260  5.0. UV melting experiments were thereafter carried
out on a UV spectrometer. Samples were dissolved in a medium
salt buffer containing 2.5 mM Na2HPO4, 5 mM NaH2PO4, 100 mM
NaCl, and 0.1 mM EDTA at pH 7.0 with 1.5 lM concentrations of
the two complementary sequences. The increase in absorbance at
260 nm as a function of time was recorded while the temperature
was increased linearly from 5 to 60 or 75 C at a rate of 0.5 or
1.0 C/min by means of a Peltier temperature programmer. The
melting temperature was determined as the local maximum of
the first derivatives of the absorbance versus temperature curve.
The melting curves were found to be reversible. All determinations
are averages of at least duplicates within ±0.5 C.
5.9. Circular dichroism spectroscopy
CD-spectra were obtained at 5 C using the same medium salt
buffer as in the UV melting experiments with 1.5 lM concentra-
tions of the two complementary sequences.
5.10. Molecular modelling
The duplexes investigated (ON3-X–Z and ON6-X–Z) were built
with a standard B-type helical geometry within the MACROMODEL
V9.1 suite of programs.14 In all the calculations the phosphodiester
backbone charge was neutralised with sodium ions, placed 3.0 Å
from the negatively charged oxygen atoms in the plane described
by the phosphorus and the non-bridging oxygen atoms. The so-
dium–oxygen distances were restrained to 3.0 Å by a force con-
stant of 418 kJ/mol Å2. The modifications X, Y and Z were each
subjected to a Monte Carlo conformational search15 rotating the
C5 (nucleobase)—C4 (triazole) bond and the N1 (triazole)—C1
(phenyl) bond to generate 1000 structures, which were minimised
to identify the lowest energy structure. The lowest energy struc-
ture obtained from the Monte Carlo search was hereafter subjected
to a 5 ns molecular dynamics simulation (simulation temperature
300 K, time step 2.2 fs, SHAKE all bonds to hydrogen), during which
500 structures were sampled and subsequently minimised. The
duplex structures were minimised using the Polak–Ribiere Conju-
gate Gradient Method, the all-atom AMBER force field16,17 and GB/
SA solvation model18 as implemented in MACROMODEL V9.1. Non-
bonded interactions were treated with extended cut-offs (van der
Waals 8.0 Å and electrostatics 20.0 Å). Oscillator strength calcula-
tions for monomer Z were performed using a Hartree–Fock water
model with the aug-pc-1 basis set in GAUSSIAN 3.19
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